Tigecycline's patent status and its implications for generic competition are complex, involving multiple patents and regulatory exclusivities. While specific patent expiry dates are not publicly detailed in the provided information, the landscape suggests potential for generic entry.
When does tigecycline's market exclusivity end?
Tigecycline benefits from regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA). These exclusivities can prevent generic versions from being approved for a certain period, even if patents have expired. The exact duration of tigecycline's market exclusivity depends on when its new drug application (NDA) was approved and any potential extensions.
Can biosimilars enter before patent expiry?
The concept of biosimilars primarily applies to biologic drugs, not small-molecule drugs like tigecycline, which are eligible for generic versions. Generic drugs can potentially enter the market once the relevant patents have expired and any applicable regulatory exclusivities have ended.
What challenges exist for generic tigecycline manufacturers?
Generic manufacturers face the challenge of navigating a complex patent landscape. Companies holding patents on tigecycline or its uses may pursue legal actions to prevent generic entry. Successfully challenging these patents or waiting for their expiry is a key hurdle for generic competition to emerge.
How does the patent situation affect tigecycline pricing?
A lack of generic competition, due to patent protections and exclusivities, typically allows the originator drug manufacturer to maintain higher pricing. The eventual entry of generic tigecycline is expected to lead to a significant decrease in prices due to market competition.
Who holds patents for tigecycline?
Pfizer originally developed and markets tigecycline under the brand name Tygacil. The company holds patents related to the drug, which are crucial in determining the timeline for generic market entry.
What are the key patents for tigecycline?
While specific patent numbers and expiry dates are not detailed, tigecycline's patent protection likely covers its chemical composition, manufacturing processes, and potentially specific therapeutic uses. These patents are the basis for extending market exclusivity.
What is the mechanism of tigecycline?
Tigecycline is a glycylcycline antibiotic. It works by inhibiting bacterial protein synthesis. It binds to the 30S ribosomal subunit of susceptible bacteria, preventing the incorporation of amino acids into elongating peptide chains, thereby halting protein production [1]. It is effective against a broad spectrum of gram-positive and gram-negative bacteria, including some resistant strains [1].
What are the clinical uses of tigecycline?
Tigecycline is indicated for the treatment of complicated skin and skin structure infections, and complicated intra-abdominal infections [1]. It is also used for community-acquired bacterial pneumonia [1]. Its use is reserved for situations where alternative treatments are not suitable, particularly given concerns about antibiotic resistance [1].
---
Sources:
1. https://www.rxlist.com/tygacil-drug.htm